Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 M4TVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoriTWM2OD1yLk[xNlM4KM7:TR?= NUPoTJRCW0GQR1XS
H4 M3O5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHPNYsyUUN3ME2wMlY3OjhizszN NET5enBUSU6JRWK=
PA-1 NYDjdVQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPBTI9KSzVyPUCuPFcxQTZizszN NXnIWnFXW0GQR1XS
NKM-1 M3XoTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFwMES5N|Eh|ryP NYHSdVl3W0GQR1XS
NEC8 NFfSSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;HS2lEPTB;MT6yNVU4OiEQvF2= MVfTRW5ITVJ?
EoL-1-cell NXv4VoNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3PeJVXUUN3ME2xMlI3PzBzIN88US=> NXf3VVdXW0GQR1XS
K5 MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;XOFFKSzVyPUGuOFIxPzJizszN MlvVV2FPT0WU
QIMR-WIL MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFwNkC4OVQh|ryP NHPhfmJUSU6JRWK=
MOLT-16 NHPJempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y5RWlEPTB;MT63PFYxPCEQvF2= MkDUV2FPT0WU
CHP-212 M1zYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTFwOEGzOlkh|ryP MV\TRW5ITVJ?
CTB-1 NYHVcIExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDvTWM2OD1{LkCyNlQ3KM7:TR?= MoPuV2FPT0WU
MOLT-4 Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJwM{K4OVMh|ryP MoPhV2FPT0WU
A101D MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELGeJZKSzVyPUKuN|UxOSEQvF2= MUfTRW5ITVJ?
DOHH-2 NHL5dHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHPTWM2OD1{LkSyNlc6KM7:TR?= NW\BN2VkW0GQR1XS
ES4 NXmxZpViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3KTWM2OD1{LkSzNVU2KM7:TR?= MYfTRW5ITVJ?
SW780 M1\iNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnZUHp2UUN3ME2yMlUxQDh|IN88US=> MVnTRW5ITVJ?
VA-ES-BJ NEnuOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF64bIpKSzVyPUKuOVQyOSEQvF2= Mn\3V2FPT0WU
RPMI-8866 MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJwNU[yNVQh|ryP MUPTRW5ITVJ?
ML-2 NUDyeZh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHo[5NKSzVyPUKuOVY2PzZizszN MkLiV2FPT0WU
MSTO-211H NVrycGJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv6[WxKSzVyPUKuOVc1PTFizszN M2j4e3NCVkeHUh?=
JVM-3 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmmxTWM2OD1{LkW5N|I1KM7:TR?= Mon5V2FPT0WU
A3-KAW MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LTbGlEPTB;Mj62NVgyQCEQvF2= NHP0SllUSU6JRWK=
DK-MG MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fRRWlEPTB;Mj62NlQ4OSEQvF2= MnrhV2FPT0WU
LNCaP-Clone-FGC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJwNkSzNVgh|ryP NXi0VFF1W0GQR1XS
HT-144 NYPn[VdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fRW2lEPTB;Mj62OFU4PyEQvF2= Mn65V2FPT0WU
NB69 MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHoTWM2OD1{Lk[1N|M1KM7:TR?= M{jNWnNCVkeHUh?=
A172 M{Wy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLhRm5pUUN3ME2yMlY4PTh6IN88US=> NUfBUXJuW0GQR1XS
RS4-11 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f2T2lEPTB;Mj63NlQxPyEQvF2= MWHTRW5ITVJ?
DU-4475 NF;2dINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnKfJRKSzVyPUKuO|k2ODJizszN NUPj[|ZWW0GQR1XS
SJSA-1 MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK4PWlKSzVyPUKuPFI2PTZizszN NXHFcYpkW0GQR1XS
BV-173 M4K4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzT[VBvUUN3ME2yMlg1PDN7IN88US=> NH7SbWlUSU6JRWK=
U-2-OS MkHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u4b2lEPTB;Mj65NVA4KM7:TR?= NWnhT|lTW0GQR1XS
CHP-134 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL2TWM2OD1{LkmzPFgzKM7:TR?= NV:5SIFWW0GQR1XS
D-502MG Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\wXVNSUUN3ME2yMlk4OTV2IN88US=> MnjKV2FPT0WU
KS-1 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C4V2lEPTB;Mz6wNVYzOyEQvF2= M2HQOnNCVkeHUh?=
A204 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXlNFNEUUN3ME2zMlA2PTh6IN88US=> M4XJSHNCVkeHUh?=
KGN NIDGb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNwMEi0PVYh|ryP NH\uNoJUSU6JRWK=
NCI-H292 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fsbWlEPTB;Mz6xNlAzQCEQvF2= NXH3RllJW0GQR1XS
CAKI-1 NEmwPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zNemlEPTB;Mz6xNlY6PCEQvF2= MXPTRW5ITVJ?
C2BBe1 NHKwPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DpU2lEPTB;Mz6xO|AzPiEQvF2= MkXUV2FPT0WU
NB10 MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DN[mlEPTB;Mz6yNFk3PiEQvF2= NGXae45USU6JRWK=
MHH-NB-11 NWfzTZNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTNwMk[4Nlch|ryP NY[zfJg5W0GQR1XS
NCI-SNU-1 M1jpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTNwMke4OFMh|ryP Mmm1V2FPT0WU
HCT-116 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTNwM{CzN|Uh|ryP M3zKbHNCVkeHUh?=
G-401 M3P0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTNwM{[zNlIh|ryP NHXPcY1USU6JRWK=
MN-60 NUjR[GZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXRcnJKSzVyPUOuOFQxQTJizszN MXHTRW5ITVJ?
SW982 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXRNFVKSzVyPUOuOVA5PDhizszN NVTZeHBEW0GQR1XS
RKO Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4foSmlEPTB;Mz61N|k{PiEQvF2= M1rwTnNCVkeHUh?=
D-283MED M2LpXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfGTVdKSzVyPUOuOVc6QDZizszN NImzW3lUSU6JRWK=
LB996-RCC MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DHXmlEPTB;Mz62NlU2QCEQvF2= M1;m[XNCVkeHUh?=
A549 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjkTWM2OD1|Lk[zOVUzKM7:TR?= NX\ZdoRbW0GQR1XS
LB2241-RCC NXvm[WJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFryZY1KSzVyPUOuOlU4ODhizszN MX7TRW5ITVJ?
SK-HEP-1 NHvBSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj5TWM2OD1|Lke0Nlk4KM7:TR?= NGLaV2hUSU6JRWK=
G-402 M1LTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTNwOEC4N|Ih|ryP M335RXNCVkeHUh?=
GOTO M1qwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn4TWM2OD1|Lki0N|M{KM7:TR?= NVTWfFR6W0GQR1XS
LOXIMVI NXn6bJh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPWfo1VUUN3ME2zMlg2Pjd3IN88US=> NInDVYFUSU6JRWK=
NH-12 NIfFN5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf3VWZKSzVyPUSuNFE6PTlizszN M{XpbXNCVkeHUh?=
CTV-1 M33RNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n2U2lEPTB;ND6wO|k4OyEQvF2= M{nFTXNCVkeHUh?=
CP50-MEL-B NUL3d4xvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rCdmlEPTB;ND6yOFM6OiEQvF2= MVXTRW5ITVJ?
RH-18 M4Labmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDybGUxUUN3ME20MlI4PzB4IN88US=> M1ewVHNCVkeHUh?=
NB17 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkiwTWM2OD12LkOxO|Y5KM7:TR?= NX[zSWlLW0GQR1XS
A375 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVf4N25XUUN3ME20MlM{PTJ2IN88US=> MYPTRW5ITVJ?
IST-MES1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTRwNEG0NVEh|ryP NGXDNI5USU6JRWK=
MZ2-MEL MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTRwNUCxOVUh|ryP NFTORm9USU6JRWK=
CAL-54 MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTRwNUOwNVkh|ryP NWPScHAyW0GQR1XS
NCI-H28 NIXoT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTRwNkK3NVch|ryP NVTvfXg6W0GQR1XS
D-247MG NUjkSlBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTRwN{WwO|Ih|ryP NUXCPXFkW0GQR1XS
NCI-H460 M3va[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXkTWM2OD12LkmxNVI4KM7:TR?= Mkf5V2FPT0WU
MCF7 MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj6TWM2OD13LkS0NlQ1KM7:TR?= NF\ZeWZUSU6JRWK=
697 NVz6e5Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTVwNES1OUDPxE1? MkTQV2FPT0WU
ONS-76 NE\2Wm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT1TWM2OD13LkW3NFA6KM7:TR?= MXTTRW5ITVJ?
C32 NHnrZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELIcFNKSzVyPUWuOlAxOjlizszN MlnQV2FPT0WU
OS-RC-2 NHLHZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHjRXZmUUN3ME21Mlc{QDh5IN88US=> Mln2V2FPT0WU
MEL-HO NXn5VmlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP5R4R[UUN3ME21Mlg2PjZ5IN88US=> M4O0WnNCVkeHUh?=
LoVo M3fLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfOTWM2OD14LkCxOlI1KM7:TR?= NED6dmdUSU6JRWK=
AGS NVzRV2M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHPV|RGUUN3ME22MlE1QDJ6IN88US=> M1nUdXNCVkeHUh?=
GI-ME-N NVXzSWZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHYV4tKSzVyPU[uNlI1OjFizszN M2HBXnNCVkeHUh?=
H-EMC-SS NHz6Z3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTZwM{i2JO69VQ>? NUjqS3BGW0GQR1XS
RVH-421 M{m2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnOTWM2OD14LkSyOFI5KM7:TR?= MnHUV2FPT0WU
SW954 NGfk[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf3c3FKSzVyPU[uOVU2PzJizszN M4PpZ3NCVkeHUh?=
NB5 NETYe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XqUGlEPTB;Nj61OlE5OyEQvF2= MYHTRW5ITVJ?
NCI-H2122 M3nLS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrWT4hMUUN3ME22MlU5Pzl|IN88US=> MVXTRW5ITVJ?
AM-38 M1vyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7Ve49KSzVyPU[uO|U3OzlizszN NIDWcYJUSU6JRWK=
KNS-81-FD MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3kOVBOUUN3ME22Mlc3PDl2IN88US=> NIO1dlVUSU6JRWK=
LS-513 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3kTWM2OD14Lke5NFI3KM7:TR?= M{LISHNCVkeHUh?=
A427 NYTYfpJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u5OWlEPTB;Nj64O|gzQSEQvF2= MoXPV2FPT0WU
WM-115 MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHuTWM2OD14LkmzNlMh|ryP NXrrWYJIW0GQR1XS
COLO-829 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fSfWlEPTB;Nz6yOFE5QCEQvF2= MYfTRW5ITVJ?
NCI-H1650 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTdwM{myNlgh|ryP NVTZOZpIW0GQR1XS
NCI-H358 NYfR[lNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTdwNES4O|kh|ryP NHfrRZJUSU6JRWK=
HT-1080 NXvYbmFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrFc4Z6UUN3ME23MlQ5OjV2IN88US=> MlyzV2FPT0WU
HCC2218 M1\HO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTMOHFKSzVyPUeuOlI6PyEQvF2= NFq5PXNUSU6JRWK=
NCI-H661 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;GOo5VUUN3ME23Mlg4ODZ7IN88US=> MXjTRW5ITVJ?
KM-H2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;F[WI5UUN3ME23Mlg5Pjl2IN88US=> NFfEd5RUSU6JRWK=
RPMI-2650 M4TVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fye2lEPTB;Nz65OFQyPCEQvF2= NF3JNnhUSU6JRWK=
NCI-H226 NHHmeWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRThwMkGxNlIh|ryP MW\TRW5ITVJ?
MKN45 M4Lqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLCTWM2OD16LkK2OlAzKM7:TR?= NWnLeGI{W0GQR1XS
D-392MG NIfZTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi3fWl[UUN3ME24MlUzPzJ{IN88US=> MVPTRW5ITVJ?
RCC10RGB NF:4UVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnZV4dCUUN3ME24Mlg3Pjl3IN88US=> Mn;LV2FPT0WU
CAL-51 Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3YTWM2OD17LkGwNlUyKM7:TR?= MonMV2FPT0WU
COLO-678 NWPrb4RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfu[2psUUN3ME25MlMzQDFzIN88US=> M3;VXHNCVkeHUh?=
SK-MEL-24 NH\VdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4izSWlEPTB;OT61OVg2PiEQvF2= M324dHNCVkeHUh?=
SK-MEL-30 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\CSmlEPTB;OT65OFQ4PiEQvF2= NYLtVYt4W0GQR1XS
MMAC-SF NXTndnNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTFyLkO5OlEh|ryP M3\DenNCVkeHUh?=
NTERA-S-cl-D1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFyLk[1NFgh|ryP M2LQNHNCVkeHUh?=
NB12 NVjZXmFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrKdnlbUUN3ME2xNU42ODNizszN Mlq4V2FPT0WU
UACC-257 MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PvT2lEPTB;MUGuPFY6PSEQvF2= NHLDdVBUSU6JRWK=
LAN-6 Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:3dmlEPTB;MUGuPVkzQCEQvF2= MWTTRW5ITVJ?
SW1573 NYDrcFRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHwbo1KSzVyPUGyMlMxQDZizszN NFLWcZBUSU6JRWK=
NMC-G1 M1rO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnz[nZKSzVyPUGyMlQyPzVizszN NXfy[XhmW0GQR1XS
SHP-77 Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\NbY5KSzVyPUGyMlU2PzRizszN MX3TRW5ITVJ?
IGROV-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[xNYhKSzVyPUGyMlY2PzNizszN NYjvSXNpW0GQR1XS
22RV1 NYH0SJVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK0OYZKSzVyPUGyMlgxPTlizszN MXfTRW5ITVJ?
SK-MEL-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjRTWM2OD1zMz6zPVc{KM7:TR?= NH3VWplUSU6JRWK=
NCI-H1563 Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHhTWM2OD1zMz60NlAzKM7:TR?= MXvTRW5ITVJ?
IGR-1 NVLQdGNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37BbWlEPTB;MUSuNFM1PyEQvF2= MmLiV2FPT0WU
EW-3 NFn0ZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr1cFVKSzVyPUG0MlE3OzlizszN M3TobHNCVkeHUh?=
JEG-3 NGmxcYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF2LkS5OVMh|ryP NH2xNpVUSU6JRWK=
ES3 NFvyclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF2Lk[1OlIh|ryP M{T0eXNCVkeHUh?=
MDA-MB-175-VII NFjqSWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvNTWM2OD1zND63NVEyKM7:TR?= M3PCRXNCVkeHUh?=
P30-OHK MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rXU2lEPTB;MUWuNFQ6PiEQvF2= M1fnWXNCVkeHUh?=
GP5d NEfQSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zuVGlEPTB;MUWuNVQ3PiEQvF2= M4DGVHNCVkeHUh?=
HMV-II MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP4TWM2OD1zNT6zN|M{KM7:TR?= MlL0V2FPT0WU
COLO-679 NYXvN4E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO5Vpp{UUN3ME2xOU42ODFizszN M2m0RnNCVkeHUh?=
JAR MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rT[WlEPTB;MUWuO|IxPSEQvF2= Mk\RV2FPT0WU
NCI-H1666 MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7Fd3JbUUN3ME2xOU46Ozl7IN88US=> M1TBe3NCVkeHUh?=
SW48 MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnnTWM2OD1zNT65OVE3KM7:TR?= NX7PWHhUW0GQR1XS
NCI-H720 NEXHWoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LPNmlEPTB;MUWuPVk5QSEQvF2= NWizeGczW0GQR1XS
HT-1197 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF4LkCzOVIh|ryP NXWwVVJGW0GQR1XS
HL-60 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDhV4dKSzVyPUG2MlA{QDRizszN MXLTRW5ITVJ?
BEN MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF4LkW2N|gh|ryP NEHZN4pUSU6JRWK=
HAL-01 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF4Lki5NFkh|ryP MXXTRW5ITVJ?
SW900 Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrIUZpKSzVyPUG2MlkyOzJizszN MUDTRW5ITVJ?
SBC-1 M4r4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF5LkW0Nlkh|ryP NIf6fWRUSU6JRWK=
SH-4 NUjhRY9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXKTWM2OD1zNz61PFQyKM7:TR?= MV7TRW5ITVJ?
UACC-62 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrIc2JKSzVyPUG3Mlc3OzdizszN M4HSSnNCVkeHUh?=
BHT-101 M{jj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\UXGRKSzVyPUG5Mlg4ODVizszN NGLmcodUSU6JRWK=
DB Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm0TWM2OD1{MT61OlQ6KM7:TR?= MYPTRW5ITVJ?
SK-MEL-1 NXnvfmVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJzLkW4O|Ih|ryP NVjMWnh7W0GQR1XS
NCI-H747 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHETWM2OD1{Mj63N|c6KM7:TR?= M4XBRnNCVkeHUh?=
SK-LU-1 M2XpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPGR4RKSzVyPUKzMlM2OjRizszN NED2R|dUSU6JRWK=
KG-1 MmraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vKb2lEPTB;MkOuOFk1PiEQvF2= M3rONHNCVkeHUh?=
LXF-289 MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HVdWlEPTB;MkOuO|E1KM7:TR?= MYDTRW5ITVJ?
HCC1954 NFPPfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXpTWM2OD1{ND64PFQ1KM7:TR?= M4frdnNCVkeHUh?=
Ramos-2G6-4C10 MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDRdWl3UUN3ME2yOk41QThzIN88US=> NIPYRZpUSU6JRWK=
DBTRG-05MG M4f0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2S5[GlEPTB;Mk[uOlQ5QCEQvF2= M2HaZXNCVkeHUh?=
NCI-H2052 MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ5LkW2PFQh|ryP MnPmV2FPT0WU
RMG-I MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjt[YxKSzVyPUK5MlQyOzlizszN NYnVNJZ2W0GQR1XS
H9 MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTNzLkOwNFgh|ryP NH3O[nRUSU6JRWK=
GR-ST M{D6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTN{LkS0OVMh|ryP NXm4PWpoW0GQR1XS
Mo-T M2L6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLVeFJKSzVyPUOyMlUxPDZizszN NUj3XVdnW0GQR1XS
SW1088 NXPr[YNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjFTWM2OD1|Mj65PFAyKM7:TR?= NGmwfI9USU6JRWK=
LB2518-MEL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4njUWlEPTB;M{OuNFc6PyEQvF2= M2rGcnNCVkeHUh?=
NCI-H82 M4e1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XJbWlEPTB;M{OuNVY3OSEQvF2= M3f2S3NCVkeHUh?=
LAMA-84 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H5NGlEPTB;M{SuOlA4OyEQvF2= NWX4NHFRW0GQR1XS
KYSE-450 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTN2Lk[3O|Yh|ryP Ml3WV2FPT0WU
LU-99A M{\jVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHYTWM2OD1|NT6wNFA4KM7:TR?= NYHXUXpTW0GQR1XS
BE-13 NH7Pe2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUi2ZYVpUUN3ME2zOU43PTR3IN88US=> M1jRZnNCVkeHUh?=
GAK Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTN3Lk[5OUDPxE1? NFnSW|FUSU6JRWK=
NCI-H1573 NISxfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TxVWlEPTB;M{WuPFgyQCEQvF2= NUXSPFd1W0GQR1XS
AsPC-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojXTWM2OD1|Nj6xOVI4KM7:TR?= M{PFenNCVkeHUh?=
HDLM-2 NX;tU5hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfON2RKSzVyPUO2MlMyPiEQvF2= Mnr4V2FPT0WU
NCI-H441 NHfUWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PnR2lEPTB;M{euNFY6OSEQvF2= Mn34V2FPT0WU
CAL-27 NFzqVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m2XmlEPTB;M{euO|I{OSEQvF2= NELxWVVUSU6JRWK=
OVCAR-3 MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorsTWM2OD1|OT6zNVgyKM7:TR?= NILRN4hUSU6JRWK=
RPMI-8226 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jmN2lEPTB;M{muOVk5KM7:TR?= Moq2V2FPT0WU
EFO-21 MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHo[FBKSzVyPUSwMlU5OTRizszN NVnucZd7W0GQR1XS
SNU-C2B NEjYfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv0eYM1UUN3ME20NU42ODh2IN88US=> NEjYdHZUSU6JRWK=
VM-CUB-1 MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn0[XFKSzVyPUSzMlgxOzdizszN MU\TRW5ITVJ?
NCI-H2087 NX6zdGJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2iyfWlEPTB;NEWuNFI{OyEQvF2= MnPqV2FPT0WU
EW-16 M1vL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTR4LkOxN|ch|ryP NUG3TIY2W0GQR1XS
SK-N-AS MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPQTJlKSzVyPUS2MlcyPjdizszN MVnTRW5ITVJ?
COR-L105 NULaV5poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTR4Lki4OVch|ryP NEW0b45USU6JRWK=
DEL NWDCcZF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTR6LkC0Nlkh|ryP M3SwZ3NCVkeHUh?=
JVM-2 MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFziSJlKSzVyPUS4MlA2PThizszN NIrlXJpUSU6JRWK=
KARPAS-45 NVnyNWpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TwN2lEPTB;NEmuOFU{QCEQvF2= NGXJUIxUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water <1 mg/mL
In vivo 5% DMSO+55% PEG 300+ddH2O 8mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID